Creating the Pick’s disease International Consortium: Association study of MAPT H2 haplotype with risk of Pick’s disease
Abstract
Background Pick’s disease (PiD) is a rare and predominantly sporadic form of frontotemporal dementia that is classified as a primary tauopathy. PiD is pathologically defined by argyrophilic inclusion Pick bodies and ballooned neurons in the frontal and temporal brain lobes. PiD is characterised by the presence of Pick bodies which are formed from aggregated, hyperphosphorylated, 3-repeat tau proteins, encoded by the MAPT gene. The MAPT H2 haplotype has consistently been associated with a decreased disease risk of the 4-repeat tauopathies of progressive supranuclear palsy and corticobasal degeneration, however its role in susceptibility to PiD is unclear. The primary aim of this study was to evaluate the association between MAPT H2 and risk of PiD.
Methods We established the Pick’s disease International Consortium (PIC) and collected 338 (60.7% male) pathologically confirmed PiD brains from 39 sites worldwide. 1,312 neurologically healthy clinical controls were recruited from Mayo Clinic Jacksonville, FL (N=881) or Rochester, MN (N=431). For the primary analysis, subjects were directly genotyped for MAPT H1-H2 haplotype-defining variant rs8070723. In secondary analysis, we genotyped and constructed the six-variant MAPT H1 subhaplotypes (rs1467967, rs242557, rs3785883, rs2471738, rs8070723, and rs7521).
Findings Our primary analysis found that the MAPT H2 haplotype was associated with increased risk of PiD (OR: 1.35, 95% CI: 1.12-1.64 P=0.002). In secondary analysis involving H1 subhaplotypes, a protective association with PiD was observed for the H1f haplotype (0.0% vs. 1.2%, P=0.049), with a similar trend noted for H1b (OR: 0.76, 95% CI: 0.58-1.00, P=0.051). The 4-repeat tauopathy risk haplotype MAPT H1c was not associated with PiD susceptibility (OR: 0.93, 95% CI: 0.70-1.25, P=0.65).
Interpretation The PIC represents the first opportunity to perform relatively large-scale studies to enhance our understanding of the pathobiology of PiD. This study demonstrates that in contrast to its protective role in 4R tauopathies, the MAPT H2 haplotype is associated with an increased risk of PiD. This finding is critical in directing isoform-related therapeutics for tauopathies.
Funding See funding section
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Mayo Clinic and University College London, as well as each sites specific funding listed in the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Mayo Clinic and University College London gave ethical approval for this work and each individual brain bank had institutional IRB approval for collection and sharing of specimens.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The PIC have built a database that contains detailed demographic, clinical, and pathological information for deidentified participants with Picks disease. Basic demographic information (e.g. age at onset, age at death, disease duration, sex, and ethnicity), family history, clinical history (e.g. behavioral and language impairments, presence of parkinsonism, upper and lower motor deficits, MMSE, and CDR), and pathological observations (e.g. immunohistochemical staining records, Thal phase, Braak stage, TDP-43 type, post-mortem intervals, brain weight, and vascular pathology), other available tissues, genetic data and clinical imaging data are available for each subject upon request. All requests must be submitted to Owen A. Ross (email: ross.owen{at}mayo.edu) or Jonathan Rohrer (email: j.rohrer{at}ucl.ac.uk).
Subject Area
- Addiction Medicine (403)
- Allergy and Immunology (712)
- Anesthesia (206)
- Cardiovascular Medicine (2967)
- Dermatology (252)
- Emergency Medicine (445)
- Epidemiology (12803)
- Forensic Medicine (12)
- Gastroenterology (830)
- Genetic and Genomic Medicine (4617)
- Geriatric Medicine (423)
- Health Economics (732)
- Health Informatics (2941)
- Health Policy (1072)
- Hematology (393)
- HIV/AIDS (931)
- Medical Education (430)
- Medical Ethics (116)
- Nephrology (475)
- Neurology (4403)
- Nursing (238)
- Nutrition (648)
- Oncology (2292)
- Ophthalmology (651)
- Orthopedics (260)
- Otolaryngology (327)
- Pain Medicine (280)
- Palliative Medicine (84)
- Pathology (502)
- Pediatrics (1199)
- Primary Care Research (502)
- Public and Global Health (6996)
- Radiology and Imaging (1542)
- Respiratory Medicine (920)
- Rheumatology (444)
- Sports Medicine (386)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)